Vir Biotechnology, Inc.

VIR

Vir Biotechnology, Inc.

VIR

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-01Shares Purchased (TTM):0Shares Sold (TTM):1,798,784

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:136,777,948Shares Outstanding:147,356,811Institutional Ownership Pct.:92.82%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	279	274	232	170	211	274	223	168	297	161	242	452
Marketable Securities Current	250	196	229	328	388	517	678	741	850	985	1,271	1,234
Restricted Cash And Cash Equivalents At Carrying V…	2	2	2	2	88	88	89	90	14	13	13	13
Equity Securities Fv Ni	4	6	6	9	7	11	4	6	4	-	10	-
Prepaid Expense And Other Assets Current	39	45	45	37	41	42	48	43	41	50	53	59
Assets Current	574	523	514	546	736	932	1,042	1,047	1,206	1,213	1,588	1,769
Intangible Assets Net Excluding Goodwill	8	8	8	8	8	8	8	19	19	22	23	25
Goodwill	17	17	17	17	17	17	17	17	17	17	17	17
Property Plant And Equipment Net	50	53	56	58	61	62	63	65	66	92	96	99
Operating Lease Right Of Use Asset	59	61	62	64	65	59	60	61	62	70	71	73
Restricted Cash And Cash Equivalents Noncurrent	7	7	7	7	7	6	6	6	6	6	6	7
Long Term Investments	475	333	315	304	286	218	190	271	280	360	105	40
Other Assets	25	24	25	16	13	6	12	12	13	12	12	15
Assets	1,215	1,026	1,003	1,019	1,193	1,308	1,399	1,498	1,670	1,794	1,919	2,045
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	18	5	10	7	12	4	5	7	4	7	6	4
Accrued Liabilities And Other Liabilities	77	68	83	68	83	104	99	95	75	72	104	146
Deferred Revenue Current	-	-	-	0	10	12	13	15	17	15	65	15
Business Combination Contingent Consideration Liab…	-	-	0	0	0	18	16	-	-	-	0	-
Liabilities Current	95	74	93	75	105	137	120	117	96	94	175	165
Deferred Revenue Noncurrent	-	-	-	-	-	-	-	-	-	2	2	53
Contract With Customer Liability Noncurrent	-	-	-	9	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	84	87	89	91	93	88	90	93	95	109	112	114
Business Combination Contingent Consideration Liab…	34	33	34	34	34	24	24	33	31	28	26	24
Other Liabilities Noncurrent	19	19	22	13	13	15	15	14	14	14	16	13
Liabilities	232	213	238	223	245	264	248	258	236	247	329	370
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	2,230	2,140	1,965	1,953	1,941	1,927	1,912	1,895	1,878	1,853	1,829	1,799
Accumulated Other Comprehensive Income Loss Net Of…	-5	-3	-2	-2	-2	-2	-2	1	-3	-2	-1	-2
Retained Earnings Accumulated Deficit	-1,243	-1,323	-1,198	-1,155	-992	-881	-760	-655	-441	-303	-238	-122
Stockholders Equity	982	813	765	796	947	1,044	1,150	1,241	1,434	1,547	1,590	1,675
Liabilities And Stockholders Equity	1,215	1,026	1,003	1,019	1,193	1,308	1,399	1,498	1,670	1,794	1,919	2,045
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	169	161	139	139	139	138	137	137	137	136	135	134
Shares Outstanding	169	161	139	139	139	138	137	137	137	136	135	134

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	2.91%	8.20%	-6.26%	-	-	-	-	-	-	-	-	-
2025	-8.69%	-4.44%	4.44%	-2.76%	8.07%	17.72%	18.89%	11.11%	40.00%	22.48%	44.68%	18.30%
2024	1.54%	-12.03%	-3.46%	-9.87%	-20.25%	-21.58%	-15.05%	-20.33%	13.45%	-14.55%	-32.18%	-43.28%
2023	-	-	-	-	-	-	11.42%	15.41%	8.33%	-15.55%	-33.19%	-18.24%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.04	7.11	5.54	7.25	7.01	6.79	8.71	8.94	12.51	12.90	9.05	10.72
Quick Ratio	5.63	6.50	5.05	6.76	6.61	6.48	8.31	8.57	12.08	12.36	8.75	10.36
Working Capital	478.78M	449.43M	421.27M	470.46M	630.70M	794.92M	922.80M	930.00M	1.11B	1.12B	1.41B	1.60B
Leverage & Debt
Debt to Equity	0.24	0.26	0.31	0.28	0.26	0.25	0.22	0.21	0.16	0.16	0.21	0.22
Debt Ratio	0.19	0.21	0.24	0.22	0.21	0.20	0.18	0.17	0.14	0.14	0.17	0.18
Efficiency & Turnover
Asset Turnover TTM	0.25	0.06	0.06	0.01	0.01	0.01	0.04	0.04	0.04	0.04	0.04	0.05
Per Share Metrics
Diluted EPS TTM	-1.49	-3.00	-3.16	-3.60	-3.97	-4.20	-3.83	-3.90	-3.55	-3.99	-4.59	-4.47
Free Cash Flow Per Share TTM	-0.90	-3.05	-2.86	-2.74	-2.79	-3.07	-3.33	-3.46	-3.37	-5.76	-5.97	-4.98
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	98.86%	98.78%	98.80%	98.85%	96.79%	93.45%
Operating Profit Margin TTM	-92.40%	-720.77%	-699.18%	-3,253.60%	-3,191.67%	-3,099.71%	-791.27%	-774.67%	-715.62%	-780.18%	-794.04%	-572.17%
Net Profit Margin TTM	-83.00%	-675.96%	-638.87%	-2,963.54%	-2,895.94%	-2,769.04%	-703.40%	-678.40%	-612.40%	-677.69%	-713.69%	-493.96%
Growth Metrics
Net Revenue Growth (1Y)	1,495.93%	213.96%	-7.61%	-78.55%	-75.91%	-73.79%	-13.90%	-35.35%	-84.02%	-82.28%	-94.67%	-94.89%
Net Income Growth (1Y)	-54.26%	-23.36%	-16.09%	-6.32%	13.91%	7.08%	-15.14%	-11.21%	84.39%	275.43%	-219.24%	-152.57%
EPS Growth (1Y)	-62.24%	-28.50%	-17.47%	-7.85%	12.08%	5.38%	-16.45%	-12.75%	81.46%	270.64%	-217.88%	-151.96%
Valuation Metrics
P/E TTM	-6.79	-2.98	-1.91	-1.59	-1.27	-1.54	-1.92	-1.92	-2.51	-2.54	-2.19	-2.09
P/B TTM	1.74	1.62	1.09	1.00	0.74	0.85	0.87	0.82	0.85	0.89	0.85	0.75
P/S TTM	5.64	20.16	12.18	47.05	36.73	42.70	13.48	13.02	15.37	17.22	15.66	10.35
Market Cap	1.71B	1.32B	835.28M	793.29M	697.78M	890.80M	1.00B	1.02B	1.21B	1.37B	1.35B	1.26B
Enterprise Value	1.42B	1.04B	594.21M	623.21M	391.50M	617.23M	681.36M	759.21M	895.22M	1.19B	1.09B	785.94M
Calculated Values
Free Cash Flow TTM	-151.28M	-449.64M	-396.61M	-380.27M	-386.64M	-422.14M	-453.65M	-473.49M	-458.78M	-778.97M	-800.36M	-668.34M
Net Debt	-287.60M	-283.04M	-241.07M	-170.08M	-306.28M	-273.57M	-318.70M	-264.33M	-317.18M	-180.47M	-261.29M	-472.35M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-01Sale

Owner: Sabatini, Brent

Title: SVP, Chief Accounting Officer

Shares: 379

Price/Share: $9.45

Value: $3,581.55

Shares Owned: 61,902

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Napolitano, Janet

Title: -

Shares: 3,200

Price/Share: $9.45

Value: $30,240.00

Shares Owned: 21,216

Relationship: Director

Ownership: Direct

2026-05-01Sale

Owner: Sato, Vicki L

Title: -

Shares: 22,000

Price/Share: $10.05

Value: $221,100.00

Shares Owned: 1,078,391

Relationship: Director

Ownership: Direct

2026-04-06Sale

Owner: De, Backer Marianne

Title: President and CEO

Shares: 72,559

Price/Share: $9.16

Value: $664,640.44

Shares Owned: 948,145

Relationship: Director,Officer

Ownership: Direct

2026-04-01Sale

Owner: Sato, Vicki L

Title: -

Shares: 22,000

Price/Share: $9.07

Value: $199,540.00

Shares Owned: 1,100,391

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-01	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	379	9.45	$3,581.55	61,902	4
2026-06-01	Napolitano, Janet	Director	-	Direct	Sale	3,200	9.45	$30,240.00	21,216	4
2026-05-01	Sato, Vicki L	Director	-	Direct	Sale	22,000	10.05	$221,100.00	1,078,391	4
2026-04-06	De, Backer Marianne	Director,Officer	President and CEO	Direct	Sale	72,559	9.16	$664,640.44	948,145	4
2026-04-01	Sato, Vicki L	Director	-	Direct	Sale	22,000	9.07	$199,540.00	1,100,391	4
2026-03-23	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	7,711	9.12	$70,324.32	61,902	4
2026-03-02	Sato, Vicki L	Director	-	Direct	Sale	22,000	9.74	$214,280.00	1,122,391	4
2026-02-25	De, Verneuil Vanina	Officer	EVP, General Counsel, Corp Sec	Direct	Sale	13,700	9.82	$134,534.00	112,982	4
2026-02-25	Eisner, Mark	Officer	EVP and Chief Medical Officer	Direct	Sale	1,889	9.82	$18,549.98	154,024	4
2026-02-24	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	1,430	9.53	$13,627.90	69,613	4
2026-02-24	De, Backer Marianne	Director,Officer	Chief Executive Officer	Direct	Sale	14,762	9.53	$140,681.86	1,020,704	4
2026-02-24	Sato, Vicki L	Director	-	Direct	Sale	42,377	10.00	$423,770.00	1,144,391	4
2026-02-24	O'Byrne, Jason	Officer	EVP & Chief Financial Officer	Direct	Sale	1,634	9.53	$15,572.02	162,615	4
2026-02-23	De, Backer Marianne	Director,Officer	Chief Executive Officer	Direct	Sale	19,039	7.45	$141,840.55	1,035,466	4
2026-02-23	Eisner, Mark	Officer	EVP and Chief Medical Officer	Direct	Sale	2,089	7.45	$15,563.05	157,529	4
2026-02-23	De, Verneuil Vanina	Officer	EVP, General Counsel, Corp Sec	Direct	Sale	4,445	7.45	$33,115.25	129,799	4
2026-02-23	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	1,829	7.45	$13,626.05	71,043	4
2026-02-23	O'Byrne, Jason	Officer	EVP & Chief Financial Officer	Direct	Sale	2,089	7.45	$15,563.05	164,249	4
2026-02-13	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	1,530	7.79	$11,918.70	47,872	4
2026-02-02	Sato, Vicki L	Director	-	Direct	Sale	22,000	7.71	$169,620.00	1,144,391	4
2026-01-02	Sato, Vicki L	Director	-	Direct	Sale	22,000	5.93	$130,460.00	1,166,391	4
2025-12-01	Sato, Vicki L	Director	-	Direct	Sale	22,000	6.00	$132,000.00	1,188,391	4
2025-12-01	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	191,854	5.98	$1,147,286.92	13,728,924	4
2025-11-28	Softbank, Vision Fund (Ai…	TenPercentOwner	-	Indirect	Sale	61,493	6.44	$396,014.92	13,920,778	4
2025-11-25	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	235,971	6.38	$1,505,494.98	14,110,209	4
2025-11-17	O'Byrne, Jason	Officer	EVP & Chief Financial Officer	Direct	Sale	6,799	5.56	$37,802.44	110,701	4
2025-11-05	De, Verneuil Vanina	Officer	EVP, General Counsel, Corp Sec	Direct	Sale	2,385	5.16	$12,306.60	78,210	4
2025-11-03	Sato, Vicki L	Director	-	Direct	Sale	22,000	5.64	$124,080.00	1,210,391	4
2025-11-03	De, Verneuil Vanina	Officer	EVP and General Counsel	Direct	Sale	1,365	5.86	$7,998.90	80,595	4
2025-10-28	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	24,453	6.50	$158,944.50	14,574,083	4
2025-10-27	Sb, Investment Advisers (…	TenPercentOwner	-	Indirect	Sale	66,403	6.05	$401,738.15	14,598,536	4
2025-10-23	Sb, Investment Advisers (…	TenPercentOwner	-	Indirect	Sale	154,383	5.99	$924,754.17	14,711,635	4
2025-10-21	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	109,675	6.30	$690,952.50	15,010,284	4
2025-10-16	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	12,844	6.10	$78,348.40	15,340,494	4
2025-10-10	Softbank, Vision Fund (Ai…	TenPercentOwner	-	Indirect	Sale	2,300	6.08	$13,984.00	15,370,009	4
2025-10-08	Sb, Investment Advisers (…	TenPercentOwner	-	Indirect	Sale	466,242	6.05	$2,820,764.10	15,621,369	4
2025-10-06	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	73,955	5.69	$420,803.95	16,159,744	4
2025-10-01	Sato, Vicki L	Director	-	Direct	Sale	22,000	5.84	$128,480.00	1,232,391	4
2025-09-02	Sato, Vicki L	Director	-	Direct	Sale	22,000	4.99	$109,780.00	1,254,391	4
2025-08-01	Sato, Vicki L	Director	-	Direct	Sale	22,000	4.99	$109,780.00	1,276,391	4
2025-07-17	Eisner, Mark	Officer	EVP and Chief Medical Officer	Direct	Sale	3,586	5.47	$19,615.42	104,618	4
2025-07-01	Sato, Vicki L	Director	-	Direct	Sale	22,000	5.10	$112,200.00	1,298,391	4
2025-06-02	Napolitano, Janet	Director	-	Direct	Sale	3,200	5.05	$16,160.00	16,416	4
2025-04-03	De, Backer Marianne	Director,Officer	Chief Executive Officer	Direct	Sale	79,712	5.95	$474,286.40	769,505	4
2025-02-26	De, Verneuil Vanina	Officer	EVP and General Counsel	Direct	Sale	7,373	9.14	$67,389.22	79,460	4
2025-02-24	De, Backer Marianne	Director,Officer	Chief Executive Officer	Direct	Sale	16,122	9.45	$152,352.90	849,217	4
2025-02-24	De, Verneuil Vanina	Officer	EVP and General Counsel	Direct	Sale	5,140	9.45	$48,573.00	86,833	4
2025-02-24	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	1,562	9.45	$14,760.90	46,627	4
2025-02-24	Hanly, Ann M.	Officer	EVP & Chief Technology Officer	Direct	Sale	14,168	9.45	$133,887.60	117,901	4
2025-02-24	Scangos, George A	Director	-	Direct	Sale	10,056	9.45	$95,029.20	698,239	4
2025-02-18	Scangos, George A	Director	-	Direct	Sale	10,964	9.81	$107,556.84	708,295	4
2025-02-13	Sabatini, Brent	Officer	SVP, Chief Accounting Officer	Direct	Sale	1,562	9.15	$14,292.30	28,189	4
2025-01-08	Sato, Vicki L	Director	-	Direct	Sale	10,960	12.52	$137,219.20	1,312,391	4
2024-12-02	De, Verneuil Vanina	Officer	EVP and General Counsel	Direct	Sale	76	8.22	$624.72	56,973	4
2024-11-06	De, Verneuil Vanina	Officer	EVP and General Counsel	Direct	Sale	4,397	10.11	$44,453.67	56,973	4
2024-11-05	De, Verneuil Vanina	Officer	EVP and General Counsel	Direct	Sale	2,347	9.47	$22,226.09	61,370	4
2024-09-09	Napolitano, Janet	Director	-	Direct	Sale	12,190	7.80	$95,082.00	11,616	4
2024-06-11	Ramasastry, Saira	Director	-	Direct	Sale	4,000	10.95	$43,800.00	14,619	4
2024-04-03	De, Backer Marianne	Director,Officer	Chief Executive Officer	Direct	Sale	72,995	9.46	$690,532.70	678,457	4
2024-04-01	Hanly, Ann M.	Officer	EVP & Chief Technology Officer	Direct	Sale	2,711	10.05	$27,245.55	132,069	4
2024-03-27	Lee, Sung	Officer	EVP & Chief Financial Officer	Direct	Sale	6,008	9.89	$59,419.12	100,492	4
2024-02-26	Scangos, George A	Director	-	Direct	Sale	17,722	11.65	$206,461.30	112,989	4
2024-02-22	Pang, Phillip	Officer	EVP & Chief Medical Officer	Direct	Sale	14,568	10.05	$146,408.40	250,111	4
2024-02-22	Hanly, Ann M.	Officer	EVP & Chief Technology Officer	Direct	Sale	12,296	10.05	$123,574.80	134,780	4
2024-02-20	Scangos, George A	Director	-	Direct	Sale	16,872	10.22	$172,431.84	140,739	4
2024-02-16	Pang, Phillip	Officer	EVP & Chief Medical Officer	Direct	Sale	3,321	10.24	$34,007.04	264,679	4
2023-06-30	Softbank, Vision Fund (Ai…	TenPercentOwner	-	Indirect	Sale	700	25.11	$17,577.00	16,684,041	4
2023-06-30	Sato, Vicki L	Director	-	Direct	Sale	18,000	24.66	$443,880.00	1,315,351	4
2023-06-29	Sb, Investment Advisers (…	TenPercentOwner	-	Indirect	Sale	89,942	25.18	$2,264,739.56	16,684,741	4
2023-06-20	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	9,902	25.18	$249,332.36	16,781,693	4
2023-06-16	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	128,144	25.73	$3,297,145.12	16,791,595	4
2023-06-14	Svf, Endurance (Cayman) L…	TenPercentOwner	-	Indirect	Sale	57,248	26.08	$1,493,027.84	16,974,921	4
2023-06-07	Pang, Phillip	Officer	Chief Medical Officer	Direct	Sale	5,000	25.95	$129,750.00	188,000	4
2023-06-05	Sb, Investment Advisers (…	TenPercentOwner	-	Indirect	Sale	5,197	27.32	$141,982.04	17,139,023	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.82%

Inst. Shares: 136,777,948

Shares Outstanding: 147,356,811

2025-12-31

82.49%

Inst. Shares: 114,261,379

Shares Outstanding: 138,520,419

2025-09-30

76.36%

Inst. Shares: 106,093,399

Shares Outstanding: 138,930,173

2025-06-30

79.07%

Inst. Shares: 109,468,792

Shares Outstanding: 138,447,469

2025-03-31

67.15%

Inst. Shares: 92,309,484

Shares Outstanding: 137,468,900

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	136,777,948	147,356,811	92.82%
2025-12-31	114,261,379	138,520,419	82.49%
2025-09-30	106,093,399	138,930,173	76.36%
2025-06-30	109,468,792	138,447,469	79.07%
2025-03-31	92,309,484	137,468,900	67.15%
2024-12-31	87,431,919	136,246,865	64.17%
2024-09-30	86,126,037	136,653,753	63.03%
2024-06-30	86,568,245	136,223,725	63.55%
2024-03-31	85,599,278	135,280,648	63.28%
2023-12-31	85,340,048	134,130,924	63.62%
2023-09-30	83,442,145	134,289,620	62.14%
2023-06-30	86,730,503	134,059,079	64.70%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Vir Biotechnology, Inc. (VIR) — SEC Financial Statements & Analysis

Vir Biotechnology, Inc. (VIR) is a biological products, (no diagnostic substances) company, incorporated in DE. Vir Biotechnology, Inc. trades on Nasdaq as: VIR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vir Biotechnology, Inc. reported a 1495.93% year-over-year revenue growth, a Gross Profit Margin of 98.86% (TTM), a Debt-to-Equity ratio of 0.24x, a Price-to-Sales (P/S) ratio of 5.64x (TTM), a Price-to-Book (P/B) ratio of 1.74x (TTM), at a market cap of $1.71B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 1495.93%
Gross Profit Margin TTM: 98.86%
Debt To Equity: 0.24x
P/S TTM: 5.64x
P/B TTM: 1.74x
Market Cap: $1.71B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Vir Biotechnology, Inc. in?

Vir Biotechnology, Inc. (VIR) operates in the Biological Products, (No Diagnostic Substances) industry.

What is VIR's market cap?

Vir Biotechnology, Inc. (VIR) has a market capitalization of $1.71B as of 2026-06-30.

What exchange does VIR trade on?

Vir Biotechnology, Inc. (VIR) trades on the Nasdaq.

Where is Vir Biotechnology, Inc. incorporated?

Vir Biotechnology, Inc. is incorporated in DE.